External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology SABCS 2025
Roche and Genentech at

SABCS 2025

December 09 - December 12
San Antonio, USA
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
11:00 PM
Duration 90mins San Antonio, USA
Analytical performance of an image analysis algorithm developed as an adjunctive aid for determining HER2 gene status from in situ hybridization
Keith A Wharton Jr, Neelima Thampy, Kathe Young-Zvandasara, Chris M Bacon, Chen-Chun Chen, Nicola Harris, Miles Howe, Anna Long, Laura Mansfield, Jennifer Ness, Sarah Dance, Landon J Inge
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 90mins San Antonio, USA
Comparative analysis of blood- and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib + fulvestrant ± inavolisib▼ in hormone receptor-positive, HER2-negative advanced breast cancer
Stephanie Hilz, Kevin Kalinsky, Dejan Juric, Nicholas Turner, Komal L. Jhaveri, Seock-Ah Im, Sibylle Loibl, Sherene Loi, Cristina Saura, Peter Schmid, Elin Shaddox, Norberto Pantoja Galicia, Cui Guo, Kate Li, Walter C. Darbonne, Rupal Desai, Pisutthida Karavagul, Junko Aimi, Stephanie Royer-Joo, Jennifer L. Schutzman, Thomas J. Stout, Chunyan Song, Philippe L. Bedard, Katherine E. Hutchinson
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 AM
Duration 90mins San Antonio, USA
Molecular features of response to palbociclib + fulvestrant ± inavolisib▼ in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Stephanie Hilz, Nicholas Turner, Kevin Kalinsky, Sibylle Loibl, Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Peter Schmid, Sherene Loi, Thomas J. Stout, Chunyan Song, Katherine E. Hutchinson, Dejan Juric
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.